Objective: To review the literature for reported cases of mania related to discontinuing antidepressant treatment, as well as for possible explanations of this phenomenon, and to present a case report.
A ntidepressants have a well-established role in the treatment of bipolar disorder (BD). There is also a known, inherent risk of antidepressant-induced mania in bipolar illness (as high as 35% [1] ) that is accepted and considered in any treatment decision. However, a paradoxical shift to mania upon withdrawal of an antidepressant is not a commonly reported occurrence. Since 1981, there have been only 17 reports of antidepressant withdrawal-induced mania in patients with unipolar depression. Most cases involved the use of tricyclic antidepressants (TCAs). There were no such case reports in patients with BD until 1998, when 2 articles were published reporting similar observations in 18 patients. Most of these cases involved the use of selective serotonin reuptake inhibitors (SSRIs). Since 1999, there have been no other reported cases to support withdrawal mania in patients with BD. We present a review of the literature and provide a supporting case report of a patient with BD who had a clear manic episode precipitated by abrupt discontinuation of nortriptyline. It is our hope that, as further cases are identified and reported, the sample size will become large enough for meaningful interpretations of apparent risk factors and correlative factors, such as antidepressant class or possible predisposition according to sex.
Method
We undertook a literature review through the PubMed index, using the key words mania, antidepressant withdrawal, and antidepressants in bipolar disorder. Identified articles were reviewed, and demographic data were pooled and tabulated for unipolar depression and BD. Recorded parameters were as follows: patient diagnosis; age; sex; antidepressant type, antidepressant dosage, and length of treatment before withdrawal; abrupt (< 5 days) vs gradual (5 days to 8 weeks) antidepressant discontinuation; onset of manic symptoms from time of antidepressant withdrawal; management of manic symptoms; thyroid status; and family history of BD. Means were calculated for each parameter unless data were unavailable, in which case ranges were recorded. Using the same key words, we searched related articles for possible explanations. Each theory was explained mechanistically and assessed for strengths and limitations.
Literature Review Results
For patients with unipolar depression, we found 17 reported cases of mania induced by antidepressant withdrawal (2-10), 12 of which involved female patients. In 1 case, sex and age were not mentioned. Eliminating this study gave an age range of 21 to 65 years (mean 39 years) for female subjects and an age range of 18 to 50 years (mean 31.3 years) for male subjects. TCAs were implicated in 12 cases. Specifically, these included amitryptiline in 5 cases; imipramine in 2 cases; desipramine in 2 cases; and nortriptyline, protryptaline, and doxepin in 1 case each. Monoamine oxidase inhibitors (MAOIs) (specifically, isocarboxazid) were implicated in 2 of the 17 cases. Of the remaining cases, 1 each involved trazodone, paroxetine, and mirtazapine. Because specific data were unavailable in some studies, it was difficult to calculate a true mean length of treatment. We therefore divided treatment length into 2 categories: # 6 weeks and > 6 weeks, since antidepressant-induced mania is known to occur in the same time period that it takes for an antidepressant to have an effect (that is, 4 to 6 weeks). In 4/17 cases, antidepressant treatment was for 6 weeks or less, and in 13/17 cases treatment was for more than 6 weeks, with a range of 9 weeks to 19 years. Withdrawal was abrupt in 8/17 cases and gradual in 9/17. The average time to onset of manic symptoms was 3.9 days, with a single outlier occurring 7 weeks after abrupt discontinuation of doxepin 25 mg 3 times daily that had been taken for 19 years. Symptoms were managed by reinstituting the antidepressant in 3/17 cases (specifically, desipramine in 2 cases and doxepin in 1 case), by starting antipsychotics in 3/17 cases, by starting antipsychotics and lithium in 2/17 cases, and by starting lithium alone in 1 of 17 case. Symptoms resolved spontaneously in 2/17 cases. Of the remaining cases, 3 refused treatment, symptom management was not reported in 2, and no treatment was necessary in 1 case. Family history was negative in 11/17 cases, positive in 2/17 cases, and not mentioned in 4/17 cases.
For patients with BD, a study by Goldstein and colleagues described 6 cases of antidepressant withdrawal-induced mania (11) . Data on age and sex were not provided. SSRIs were implicated in 3/6 cases (specifically, sertraline in 2 cases and fluoxetine in 1 case). TCAs were implicated in 2/6 cases (specifically, 1 case each involving desipramine and nortyrptiline). The last case implicated venlafaxine. Treatment length was 35 to 480 days, with a mean of 203 days (6.5 months). In 1 of the 6 cases, the treatment length was only 5 weeks, and the antidepressant was abruptly withdrawn in a single day. Withdrawal was gradual in the remaining 5 cases, with a mean taper length of 23.4 days and a range of 11 to 43 days. The average time to onset of manic symptoms was 13.5 days, with a range of 1 to 23 days. Symptoms were managed by antidepressant reinstitution in 1 case and by starting antipsychotics in 4 cases. In 1 case, symptoms were untreated. No information regarding family history of BD or thyroid status was provided in any of the 6 cases. Goldstein and colleagues refer to a finding by Shriver and others, who reported 12 such cases in a retrospective review presented at the 151st Annual APA meeting. However, apart from naming the classes of antidepressants implicated, they provide no further data from this report.
Our own case example (12) involved a 74-year-old man with a 30-year history of BD who had been on nortriptyline 100 mg daily for over 12 months. He abruptly stopped taking it and developed mania symptoms within 2 days. His symptoms were successfully treated with valproic acid 500 mg twice daily and risperidone 1.5 mg twice daily. He was known to be euthryoid, and his only psychiatric family history was that his mother suffered from depression.
When combined, the findings reported by Goldstein and colleagues (including those cited for Shriver and others) (11) and our own case report (12) Goldstein and colleagues considered several differential diagnoses to explain this phenomenon, including antidepressant-induced mania leading to antidepressant discontinuation, agitated depression, physiological withdrawal syndrome, and spontaneous mania as the natural course of the illness (11) . When these potential confounders were evaluated, however, they were ruled out as differential diagnostic considerations. Mania associated with antidepressant withdrawal differs in several aspects from spontaneous mania or from antidepressant-induced mania. Table 1 provides some distinguishing features of each mania type, as observed by the reviewed reports; it may aid in identifying more cases.
Discussion
Our case example illustrates and supports the previous observations of a similar phenomenon in patients with BD. Further, when the pooled demographic data provided in Tables 2 and 3 are examined, it is interesting to note certain trends. For example, among patients with unipolar depression, mania induced by antidepressant withdrawal appears to occur more frequently with TCAs. Among patients with BD, however, it appears more frequently with the SSRIs. In addition, antidepressant withdrawal-induced mania seems to occur more frequently in female patients with unipolar depression than it does in male patients. (Unfortunately, information on sex was not available for the study population with BD.) These findings are interesting, but thus far anecdotal. They may provoke some questions regarding the establishment of possible risk factors for developing this condition when enough reported cases exist for a sufficiently large sample size.
Several hypotheses have been postulated to explain the pathophysiology of antidepressant withdrawal-induced mania. They include a cholinergic-monoaminergic interaction hypothesis (13, 14) , hyposerotonergic mania (15), noradrenergic hyperactivity (2,10,16), rapid eye movement (REM) sleep rebound (4, (17) (18) (19) , and hyperdopaminergic mania (9) . 
The Cholinergic-Monoaminergic Interaction Hypothesis
The cholinergic-monoaminergic interaction model proposed by Dilsaver and colleagues (13, 14) is one of the most studied hypotheses. Because of the antimuscarinic properties of TCAs, chronic administration leads to increased cholinergic receptor sensitivity in both the cholinergic-inhibitory and the monoaminergic-activating systems. This in turn reduces the sensitivity of such monoaminergic receptors as the dopaminergic and noradrenergic receptors. Withdrawing the antidepressant therefore precipitates cholinergic overdrive, thus activating the cholinergic-monoaminergic system, which acts to maintain homeostatic balance. Thus, in response to cholinergic overdrive, the monoaminergic synthetic pathways are activated; a measurable significant increase in tyrosine hydroxylase (the enzyme catalyzing the rate-limiting step in catecholamine synthesis) has been reported (14) . Once the cholinergic overdrive abates, the monoaminergic system usually downregulates in parallel. In some patients, however, the system fails to downregulate, resulting in a state of relative monoaminergic excess and associated hypomania or mania. Although much evidence supports this hypothesis, it does not apply to drugs with weak anticholinergic properties, such as trazodone and MAOIs. Perhaps, in addition to the cholinergic-monoaminergic interaction, some other mechanism causes similar activation upon withdrawal of weak anticholinergic drugs.
Hyposerotonergic Mania
The hyposerotonergic mania proposed by Zajecka and colleagues (15) applies to any antidepressant that potentiates, by whatever mechanism, the net concentration of serotonin in the synaptic cleft. TCAs, SSRIs, SNRIs, and trazodone all increase serotonin by blocking the presynaptic serotonin reuptake receptor. MAOIs increase serotonin by preventing its degradation by monoamine oxidase-A. The relative increase in serotonin in the synaptic cleft is thought to downregulate the postsynaptic serotonin receptors after prolonged exposure to antidepressants. Once the antidepressant is withdrawn, the presynaptic serotonin reuptake receptor is no longer blocked, leading to rapid reuptake of serotonin and a decreased concentration in the synaptic cleft. In the case of MAOIs, the degradation of serotonin is no longer blocked, again leading to its decreased concentration in the synaptic cleft. The reduction in serotonin leads to acute upregulation of the postsynaptic serotonin receptors, which then increases serotonin transmission through neuronal circuits and therefore increases the neuronal firing rate. This is thought to be the final pathway in the development of hyposerotonergic mania. The hypothesis, however, has yet to be investigated.
Noradrenergic Hyperactivity
To explain several observations of a TCA-withdrawal syndrome, Charney and colleagues provided evidence for noradrenergic hyperactivity following abrupt discontinuation of TCAs in 7 patients with unipolar depression (16) . In these subjects, they demonstrated urinary and plasma increases in 3-methoxy-4-hydroxyphenylethylene glycol (MHPG), reflecting increased norepinephrine turnover. They measured an increase in plasma and urinary MHPG of 26% and 39%, respectively, 1 week after TCA discontinuation and and increase of 74% and 61%, respectively 2, weeks after TCA discontinuation. Despite these clear elevations in plasma and urinary MHPG, only 1 patient demonstrated hypomanic behaviour as well as anxiety with panic attacks; 1 patient demonstrated increased anxiety that did not correlate with daily changes in MHPG; 1 patient's depression improved; and the rest showed no change. Therefore, MHPG levels may not correlate as well as expected with symptomatology.
Rapid Eye Movement (REM) Sleep Rebound
There have been several studies in both animals and humans that demonstrate high voltage slow wave patterns characteristic of non-REM sleep in response to high dosages of atropine and other anticholinergic agents (2, (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) . This is in contrast to cholinergic agents, which promote REM sleep. REM sleep is known to be accompanied by increased cortical release of acetylcholine (39) that is temporally associated with EEG desynchronization and behavioural arousal (14 or at least a diminution of slow wave sleep, both of which have been reported to be associated with relief of depression and the precipitation of mania or hypomania" (4, 18, 19) . Once again, this does not explain the precipitation of mania upon withdrawal of drugs with weak anticholinergic activity.
Hyperdopaminergic Mania
Some studies suggest that chronic treatment with MAOIs induces a subsensitivity of dopamine autoreceptors (40, 41) and that such treatment therefore acts as an agonist to the dopamine autoreceptor, inducing a state of low dopamine. Rothschild proposed the opposite effect when the MAOI is withdrawn: loss of the agonist autoreceptor effects should lead to hyperdopaminergia, owing to decreased uptake of dopamine by the autoreceptor (9) . He further pointed out that this mechanism would account not only for MAOIwithdrawal mania but also for mania seen after discontinuation of TCAs, as well as for the psychosis and paranoia seen after amphetamine withdrawal, since they are both also known to induce a subsensitivity of the dopamine autoreceptors (41) .
Conclusions
Antidepressant withdrawal-induced mania is an interesting phenomenon distinct from antidepressant-induced mania or physiological drug withdrawal. It does not appear to coincide with the natural course of BD. Withdrawal-induced cholinergic overdrive and the action of the cholinergic-noradrenergic system remains the most investigated hypothesis for explaining antidepressant withdrawal-induced mania. In summary, this hypothesis proposes that, upon cholinergic overdrive, the monoaminergic synthetic pathways are activated in an effort to maintain homeostatic balance. Once the cholinergic overdrive abates, the monoaminergic system usually downregulates in parallel. In some patients, the system fails to downregulate, leading to a state of relative monoaminergic excess and associated hypomania or mania. However, this hypothesis is limited by its inability to explain similar observations involving antidepressants with weaker anticholinergic activity. If there were a way of predicting with some certainty which patients might be at risk for mania induced by antidepressant withdrawl, we could potentially prevent it. For example, it was interesting to note the higher proportion of patients on TCAs and of female patients affected. Its occurrence implies a higher incidence of diagnosing BD and, therefore, of treatment with mood stabilizers. With increasing reports of this phenomenon, it may be possible to develop its relation to some of the reported parameters.
There is a strong suggestion that the constant switching of antidepressants in patients (iatrogenesis) may induce rapid cycling in the population with BD. 
